Insider
ELI Lilly & CoLLY

Eli Lilly continues clinical research in September 2026

Between September 14 and September 29, 2026, Eli Lilly conducted several clinical trials, including studies of new compounds and the completion of a Phase 4 trial for diabetes treatment. These activities aim to assess the therapeutic potential of experimental agents and new indications for existing drugs.

Verified against 6 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
Rows of lab tubes sit in a tray
Photo by Nathan Rimoux on Unsplash
153
Diabetes trial participants

Key points

  • The company conducted Phase 1 studies for several new compounds.
  • The studies involve patients with various conditions, including cancer, diabetes, and alopecia.

Clinical trials and completed studies.

The company conducted Phase 1 studies for several new compounds. The LY4064912 study enrolled 77 participants, the LY4057996 trial expects 124 individuals, and the eloralintide study aims to enroll 58 participants.

During this period, a Phase 4 trial involving 153 patients with type 2 diabetes was completed. The study evaluated the combination of insulin lispro and insulin glargine.

Participants in studies.

The studies involve patients with various conditions, including cancer, diabetes, and alopecia. In particular, a Phase 2 trial of baricitinib for central centrifugal cicatricial alopecia was completed, where 17 of 27 participants completed the full 52-week therapy course.

Next steps in drug assessment.

Further analysis of results and updates to trial registries will help determine the prospects of these developments. The success of bringing new drugs to market depends on meeting regulatory milestones and proving safety and efficacy.

Original sources

  1. NCT03531645: Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma (ACTIVE_NOT_RECRUITING)September 14, 2026SHA-256 of our archived copy 8e2890c79a22…
  2. NCT07152002: A Study of LY4064912 in Healthy Participants and With Overweight or Obesity (TERMINATED)September 14, 2026SHA-256 of our archived copy d8d34f46a720…
  3. NCT06370715: A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India (COMPLETED)September 28, 2026SHA-256 of our archived copy bbe7d45812f6…
  4. NCT07843732: Baricitinib for Central Centrifugal Cicatricial Alopecia in Adults of African Descent (COMPLETED)September 28, 2026SHA-256 of our archived copy e1962cd78f75…
  5. NCT06945406: A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes (RECRUITING)September 29, 2026SHA-256 of our archived copy c13938de086f…
  6. NCT07701083: A Study of Eloralintide (LY3841136) in Healthy Participants (ACTIVE_NOT_RECRUITING)September 29, 2026SHA-256 of our archived copy 8f93a002c9c4…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards